Cytokinetics (CYTK) stock price, revenue, and financials

Cytokinetics market cap is $698.5 m, and annual revenue was $26.87 m in FY 2019

$698.5 M

CYTK Mkt cap, 27-Mar-2020

$26.9 M

Cytokinetics Revenue FY, 2019
Cytokinetics Net income (FY, 2019)-121.7 M
Cytokinetics EBIT (FY, 2019)-98.9 M
Cytokinetics Cash, 31-Dec-201936.4 M
Cytokinetics EV714 M

Cytokinetics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

4.0m7.6m30.6m46.9m28.7m106.4m13.4m31.5m26.9m

Revenue growth, %

53%(39%)271%

R&D expense

37.2m35.6m49.5m44.4m46.4m59.9m90.3m89.1m86.1m

General and administrative expense

13.6m12.4m15.1m17.3m19.7m27.8m36.5m31.3m39.6m

Operating expense total

52.0m48.1m64.5m61.7m66.1m87.7m126.8m120.4m125.7m

EBIT

(48.0m)(40.5m)(33.9m)(14.8m)(37.4m)18.7m(113.4m)(88.9m)(98.9m)

EBIT margin, %

(1199%)(535%)(111%)(31%)(131%)18%(848%)(282%)(368%)

Interest expense

104.0k3.0k94.0k464.0k2.6m4.2m

Interest income

83.0k177.0k101.0k

Pre tax profit

(47.9m)(40.4m)(33.7m)(14.6m)(37.5m)16.5m(127.8m)(106.3m)

Income tax expense

Net Income

(47.9m)(40.4m)(33.7m)(14.6m)(37.5m)16.5m(127.8m)(106.3m)(121.7m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

1.1m1.4m1.8m1.8m1.7m821.0k1.0m4.5m8.0m7.8m9.4m4.4m6.5m7.9m8.4m5.8m59.0m4.2m3.1m6.2m5.3m6.2m10.6m8.5m7.1m6.1m

R&D expense

10.5m8.9m8.7m8.2m8.8m9.8m12.3m13.4m12.5m11.7m11.4m9.0m12.6m11.6m13.5m9.7m19.3m19.3m19.8m24.9m22.1m21.6m21.4m23.5m24.0m20.2m

General and administrative expense

4.2m3.2m3.1m2.6m3.0m3.6m3.7m3.6m4.3m4.5m4.0m4.4m4.5m5.3m6.8m7.1m7.2m8.1m8.4m9.7m9.3m8.0m7.2m9.4m9.8m9.8m

Operating expense total

14.7m12.1m11.8m10.8m11.8m13.5m16.1m17.1m16.7m16.2m15.4m13.3m17.1m16.8m20.4m16.8m26.6m27.4m28.2m34.6m31.4m29.6m28.6m33.0m33.9m30.0m

EBIT

(13.6m)(10.7m)(9.9m)(9.0m)(10.1m)(12.6m)(15.1m)(12.6m)(8.8m)(8.4m)(6.0m)(8.9m)(10.6m)(8.9m)(12.0m)(11.0m)32.5m(23.3m)(25.2m)(28.4m)(26.1m)(23.4m)(17.9m)(24.5m)(26.7m)(23.9m)

EBIT margin, %

(1296%)(748%)(546%)(486%)(588%)(1540%)(1493%)(282%)(110%)(108%)(64%)(202%)(162%)(112%)(142%)(190%)55%(560%)(825%)(460%)(496%)(377%)(168%)(290%)(374%)(395%)

Interest expense

15.0k29.0k12.0k13.0k1.0k28.0k4.0k1.0k26.0k33.0k27.0k37.0k38.0k501.0k600.0k111.0k436.0k612.0k779.0k842.0k1.1m1.3m1.1m1.0m1.0m

Interest income

8.0k30.0k28.0k23.0k23.0k26.0k37.0k38.0k114.0k

Pre tax profit

(13.6m)(10.6m)(9.9m)(8.9m)(10.0m)(12.6m)(15.0m)(12.6m)(8.7m)(8.4m)(6.0m)(8.9m)(10.6m)(8.8m)(12.5m)(11.6m)31.9m(25.9m)(32.4m)

Income tax expense

Net Income

(13.6m)(10.6m)(9.9m)(8.9m)(10.0m)(12.6m)(15.0m)(12.6m)(8.7m)(8.4m)(6.0m)(8.9m)(10.6m)(8.8m)(12.5m)(11.6m)31.9m(25.9m)(29.1m)(32.4m)(30.3m)(27.5m)(22.0m)(29.4m)(32.1m)(29.6m)

Cytokinetics Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

18.8m14.9m20.2m20.2m65.1m66.9m125.2m42.3m36.4m

Accounts Receivable

1.1m2.2m5.2m

Prepaid Expenses

2.1m2.4m1.6m1.3m1.7m4.3m2.2m3.5m

Inventories

Current Assets

51.1m76.4m79.3m131.1m113.1m158.6m274.3m207.7m233.8m

PP&E

1.3m997.0k1.2m1.6m1.8m3.6m3.6m3.2m4.5m

Total Assets

52.8m77.6m83.2m133.0m115.2m170.1m294.8m211.2m289.8m

Accounts Payable

1.2m2.0m3.7m1.4m2.2m4.2m5.3m3.8m8.2m

Short-term debt

2.5m2.6m4.6m

Current Liabilities

4.6m7.1m26.7m23.9m31.6m33.3m32.4m22.2m26.0m

Long-term debt

14.6m27.4m31.8m39.8m47.2m

Total Debt

14.6m29.9m31.8m42.4m51.9m

Total Liabilities

4.6m7.5m28.7m40.9m46.6m75.8m185.0m185.2m300.8m

Common Stock

75.0k143.0k31.0k39.0k40.0k54.0k55.0k59.0k

Preferred Stock

Additional Paid-in Capital

456.6m518.8m537.0m589.3m603.1m612.5m755.5m768.7m853.3m

Retained Earnings

(408.5m)(448.9m)(482.6m)(497.2m)(534.7m)(518.3m)(646.1m)(743.3m)(865.0m)

Total Equity

48.2m70.1m54.4m92.1m68.6m94.4m109.8m25.9m(10.9m)

Debt to Equity Ratio

0.2 x0.3 x0.3 x1.6 x

Debt to Assets Ratio

0.1 x0.2 x0.1 x0.2 x

Financial Leverage

1.1 x1.1 x1.5 x1.4 x1.7 x1.8 x2.7 x8.1 x-26.5 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

23.8m18.6m17.8m63.7m15.4m13.2m17.1m19.3m13.3m12.4m12.9m22.5m24.8m26.0m42.3m27.7m30.3m49.4m100.7m116.3m115.0m47.0m27.6m39.4m34.4m39.6m

Accounts Receivable

10.0m37.0k236.0k9.2m4.2m9.0m6.6m

Prepaid Expenses

2.9m2.2m2.1m2.5m3.2m1.7m2.0m1.7m1.6m2.0m1.8m2.0m2.7m2.7m6.3m2.6m3.6m4.9m4.4m2.3m1.7m1.9m3.1m2.5m3.9m

Current Assets

69.8m59.9m45.2m93.0m78.8m63.7m93.6m83.3m86.1m80.1m81.5m110.8m107.9m100.5m106.1m96.6m148.2m211.0m317.0m322.0m272.3m244.2m227.3m186.4m185.0m176.5m

PP&E

1.7m1.5m1.1m994.0k906.0k898.0k809.0k804.0k1.5m1.5m1.5m1.6m1.6m1.5m1.8m1.7m2.0m3.5m3.3m3.3m3.2m2.6m2.7m3.2m2.9m3.6m

Total Assets

72.2m61.8m46.5m94.1m85.3m64.7m94.6m88.0m107.3m96.1m87.2m122.2m112.7m102.2m113.2m106.2m158.2m265.4m340.6m326.3m279.9m247.2m230.3m198.6m198.2m187.4m

Accounts Payable

1.0m1.5m926.0k1.0m1.5m1.1m1.8m1.8m1.7m985.0k1.6m1.4m1.6m1.9m547.0k2.8m668.0k3.0m1.8m4.1m2.4m1.3m2.0m2.5m5.2m3.4m

Short-term debt

4.8m7.3m9.8m1.7m3.8m6.2m

Current Liabilities

5.5m5.0m4.5m4.0m4.6m5.8m34.0m45.0m19.8m16.9m13.0m25.4m29.1m30.1m24.7m26.3m29.3m36.8m31.1m42.4m38.5m27.3m21.5m26.3m22.0m21.5m

Long-term debt

29.5m29.6m29.7m25.2m22.8m20.5m32.0m30.7m38.1m41.7m48.8m48.0m

Total Debt

29.5m29.6m29.7m4.8m7.3m30.3m32.0m32.4m41.9m42.6m44.5m44.8m

Total Liabilities

5.5m5.0m4.5m4.1m4.7m6.3m42.6m48.3m21.1m17.4m13.6m38.1m37.8m34.9m55.3m57.4m74.9m170.0m165.6m179.3m180.3m172.1m178.2m195.2m203.1m207.3m

Common Stock

72.0k72.0k78.0k133.0k142.0k147.0k29.0k29.0k36.0k37.0k37.0k39.0k39.0k40.0k40.0k41.0k43.0k53.0k54.0k54.0k55.0k55.0k55.0k58.0k59.0k

Preferred Stock

Additional Paid-in Capital

452.6m453.3m460.4m517.2m517.9m519.8m528.5m528.8m577.5m578.4m579.3m590.2m591.5m592.8m604.9m607.3m609.9m639.5m748.3m752.2m757.4m762.9m766.0m775.4m799.1m813.7m

Retained Earnings

(386.0m)(396.6m)(418.4m)(427.4m)(437.4m)(461.5m)(476.5m)(489.1m)(491.3m)(499.7m)(505.7m)(506.1m)(516.7m)(525.5m)(547.2m)(558.8m)(526.9m)(544.2m)(573.2m)(605.6m)(658.3m)(688.2m)(714.4m)(772.7m)(804.8m)(834.4m)

Total Equity

66.7m56.7m42.0m90.0m80.6m58.4m52.0m39.8m86.2m78.7m73.6m84.2m74.9m67.3m57.9m48.7m83.3m95.4m175.0m147.0m99.6m75.2m52.1m3.4m(4.9m)(19.9m)

Debt to Equity Ratio

0.5 x0.6 x0.4 x0.1 x0 x0.2 x0.3 x0.4 x0.8 x12.6 x-9.1 x-2.3 x

Debt to Assets Ratio

0.3 x0.3 x0.2 x0 x0 x0.1 x0.1 x0.1 x0.2 x0.2 x0.2 x0.2 x

Financial Leverage

1.1 x1.1 x1.1 x1 x1.1 x1.1 x1.8 x2.2 x1.2 x1.2 x1.2 x1.5 x1.5 x1.5 x2 x2.2 x1.9 x2.8 x1.9 x2.2 x2.8 x3.3 x4.4 x58.9 x-40.5 x-9.4 x

Cytokinetics Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(25.3m)(36.0m)(9.9m)(18.9m)(28.9m)(12.6m)(27.7m)(40.2m)(8.7m)(17.1m)(23.1m)(8.9m)(19.4m)(8.8m)(12.5m)(24.1m)7.8m(25.9m)(54.9m)(87.3m)(30.3m)(57.8m)(79.8m)(29.4m)(61.5m)(91.1m)

Depreciation and Amortization

813.0k1.1m178.0k322.0k462.0k124.0k244.0k345.0k105.0k227.0k353.0k145.0k292.0k170.0k340.0k517.0k421.0k860.0k1.3m673.0k1.3m1.6m286.0k566.0k902.0k

Accounts Receivable

24.0k(10.0m)1.1m876.0k(8.0m)(1.9m)(6.8m)(4.3m)

Accounts Payable

(41.0k)422.0k(257.0k)(137.0k)334.0k(800.0k)(72.0k)(103.0k)(2.1m)(2.5m)(1.9m)95.0k311.0k1.9m(1.5m)841.0k(1.3m)(726.0k)(1.9m)1.5m(2.8m)(3.9m)(3.2m)(1.2m)1.4m(352.0k)

Cash From Operating Activities

(25.4m)(34.6m)(8.7m)(17.4m)(26.3m)(12.2m)(5.6m)4.7m(17.8m)(27.2m)(36.7m)34.4m25.2m(17.5m)(28.7m)(40.8m)(20.9m)(52.2m)(77.7m)(29.8m)(56.7m)(88.9m)(26.9m)(51.6m)(71.9m)

Purchases of PP&E

(317.0k)(418.0k)(13.0k)(20.0k)(66.0k)(177.0k)(221.0k)(290.0k)(333.0k)(757.0k)(857.0k)(130.0k)(305.0k)(420.0k)(436.0k)(742.0k)(1.4m)(1.6m)(2.1m)(261.0k)(321.0k)(679.0k)(257.0k)(307.0k)(1.3m)

Cash From Investing Activities

12.2m16.5m5.1m3.5m(35.4m)10.5m260.0k(7.3m)(28.9m)(20.4m)(10.4m)(32.1m)(20.7m)(20.2m)(24.1m)(10.1m)(112.3m)(136.2m)(96.6m)20.1m(24.1m)(21.4m)19.6m16.9m30.6m

Cash From Financing Activities

19.4m19.2m2.7m58.7m58.3m5.0k7.5m7.0m39.8m39.8m39.8m65.0k106.0k14.9m15.5m16.2m115.7m222.3m223.7m(524.0k)2.5m12.7m4.4m26.8m38.7m

Net Change in Cash

6.3m1.1m(1.0m)44.8m(3.4m)(1.7m)2.2m4.4m(6.9m)(7.8m)(7.3m)2.3m4.6m(22.8m)(37.4m)(34.8m)(17.5m)33.8m49.4m(10.2m)(78.3m)(97.6m)(2.8m)(7.9m)(2.6m)

Income Taxes Paid

1.0k1.0k

Cytokinetics Ratios

USDY, 2019

EV/EBIT

-7.2 x

EV/CFO

-7.9 x

Financial Leverage

-26.5 x

Cytokinetics Employee Rating

3.631 votes
Culture & Values
3.5
Work/Life Balance
3.3
Senior Management
3.4
Salary & Benefits
3.7
Career Opportunities
3.2
Source